At 8.1% CAGR, Asia Pacific Transfection Reagents and Equipment Market is Projected to be Worth US$ 414.29 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Asia Pacific transfection reagents and equipment market was valued at US$ 222.23 million in 2022 and is expected to reach US$ 414.29 million by 2030, registering a CAGR of 8.1% from 2022 to 2030. Ramping up small-scale processes to large-scale processes and strategic initiatives by companies are among the critical factors attributed to the Asia Pacific transfection reagents and equipment market expansion.

Transfection is the complex step in the overall process of developing a viral vector, which includes adenovirus, adeno-associated virus, and lentivirus. As the manufacturing processes are scaled up, transient transfection must also be ramped up. Process equipment vendors, drug developers, and raw material suppliers are focusing on collaborations to develop cost-effective, practical, and platformizable solutions for the rapid development and scaling up of viral vector manufacturing processes. On small scales, with planned material volumes and transfer & mixing times, transfecting cells with multiple plasmids becomes feasible. Scaling up requires experience in industrializing the transfection step since most companies only have transfection experience at the lab level. However, the volume of cell-culture media and transfection reagents required for scaling up the process to a larger level can be impractical, which emphasizes the need for optimization. Nonetheless, broadening the scale of production has become common in recent years with the surging demand for viral vectors. With numerous challenges associated with large-scale transfection processes, the best approach to increase production is by reducing the process rather than scaling up the process. This top-down approach allows clear identification of the conditions that will impact the process at the industrial level such as the volume of transfection complex solution. This approach also facilitates process optimization and decision-making. The development of such approaches to ramp up the small-scale transfection processes acts as an opportunity for the growth of the Asia Pacific transfection reagents and equipment market.

On the contrary, high cost of instruments and consumables hampers the growth of Asia Pacific transfection reagents and equipment market.

Based on product, the Asia Pacific transfection reagents and equipment market is bifurcated into reagents and instruments. The reagents segment held 74.5% share of the Asia Pacific transfection reagents and equipment market in 2022, amassing US$ 165.60 million. It is projected to garner US$ 311.61 million by 2030 to expand at 8.2% CAGR during 2022-2030.

In terms of method, the Asia Pacific transfection reagents and equipment market is segmented into viral methods, non viral methods, and hybrid methods. The non-viral methods segment held 56.8% share of the Asia Pacific transfection reagents and equipment market in 2022, amassing US$ 126.23 million. It is estimated to garner US$ 238.08 million by 2030 to expand at 8.3% CAGR during 2022-2030. The viral segment is subcategorized into retrovirus, adenovirus, adeno associated virus, and herpes virus. The non-viral segment is bifurcated into physical/mechanical method and chemical method. Further, the physical/mechanical method segment is sub categorized into electroporation, microinjection, biolistic method, laser method, magnetofection, and sonoporation. Also, the chemical method segment is sub categorized into liposomal based/high lipid and non-liposomal/high lipid based.

By application, the Asia Pacific transfection reagents and equipment market is segmented into biomedical research, protein production, and therapeutic delivery. The biomedical research segment held 52.3% share of Asia Pacific transfection reagents and equipment market in 2022, amassing US$ 116.27 million. It is predicted to garner US$ 219.79 million by 2030 to expand at 8.3% CAGR during 2022-2030.

Based on end user, the Asia Pacific transfection reagents and equipment market is bifurcated into academics & research institutes and pharmaceutical & biotechnology companies. The academics & research institutes segment held 65.5% share of the Asia Pacific transfection reagents and equipment market in 2022, amassing US$ 145.60 million. It is projected to garner US$ 269.69 million by 2030 to expand at 8.0% CAGR during 2022-2030.

Based on country, the Asia Pacific transfection reagents and equipment market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China held 39.8% share of Asia Pacific transfection reagents and equipment market in 2022, amassing US$ 88.48 million. It is projected to garner US$ 171.42 million by 2030 to expand at 8.6% CAGR during 2022-2030.

Key players operating in the Asia Pacific transfection reagents and equipment market are Thermo Fisher Scientific Inc, Promega Corp, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Mirus Bio LLC, QIAGEN NV, Merck KGaA, Lonza Group AG, MaxCyte Inc, and Polyplus-Transfection SA

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com